Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PLEC | Q15149 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL6810203 | 0.91 | APP (0.86) | APPCYP1A2SNCAESR1ESR2 | |
| Methoxymethane SCHEMBL2784008 | 0.90 | APP (0.89) | APPCYP1A2SNCAESR1ESR2 | |
| SCHEMBL8066 | 0.89 | APP (1.00) | APPCYP1A2SNCAESR1ESR2 | |
| SCHEMBL29456578 | 0.88 | APP (0.97) | APPCYP1A2SNCAESR1ESR2 | |
| SCHEMBL1095367 | 0.88 | APP (0.97) | APPCYP1A2SNCAESR1ESR2 | |
| SCHEMBL7113427 | 0.88 | APP (0.97) | APPCYP1A2SNCAESR1ESR2 | |
| Ammonia Solution, Strong SCHEMBL29419058 | 0.88 | APP (0.97) | APPCYP1A2SNCAESR1ESR2 | |
| Propionic Acid SCHEMBL21043901 | 0.88 | APP (0.80) | APPCYP1A2SNCAESR1ESR2 | |
| Propionic Acid SCHEMBL21043899 | 0.88 | APP (0.80) | APPCYP1A2SNCAESR1ESR2 | |
| Acetic Acid SCHEMBL233000 | 0.86 | APP (0.86) | APPCYP1A2SNCAESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106544399-B | Application of high-specificity fluorescent probe for detecting cytochrome P4501A1 | 苏州尚稷电子科技有限公司 | 2020-04-03 | — | — | CN | claimed |
| CN-106544399-A | The application of the high specific fluorescence probe of one class detection Cytochrome P450 1A1 | 苏州尚稷电子科技有限公司 | 2017-03-29 | — | — | CN | claimed |
| WO-1994019487-A1 | ISOLATION OF TROPHOBLASTS | APROGENEX, INC. (US) | 1994-09-01 | — | — | WO | claimed |
| US-5110725-A | Optical probe for the cytochrome P-450 cholesterol side chain cleavage enzyme | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1992-05-05 | — | — | US | claimed |
| US-20240219393-A1 | ALUMINOSILICATE NANOPARTICLE SENSORS AND USES THEREOF | CORNELL UNIVERSITY | 2024-07-04 | — | — | US | disclosed |
| US-20220162693-A1 | MASSIVELY PARALLEL SEQUENCING USING UNLABELED NUCLEOTIDES | MGI TECH CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3877548-A1 | MASSIVELY PARALLEL SEQUENCING USING UNLABELED NUCLEOTIDES | MGI Tech Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| US-20210246109-A1 | POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2021-08-12 | — | — | US | disclosed |
| CN-106544399-B | Application of high-specificity fluorescent probe for detecting cytochrome P4501A1 | 苏州尚稷电子科技有限公司 | 2020-04-03 | — | — | CN | disclosed |
| EP-3269822-A1 | METHODS AND COMPOSITIONS TO DETECT A BIOLOGICAL ACTIVITY | 3M Innovative Properties Company (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2643471-B1 | METHODS AND COMPOSITIONS TO DETECT A BIOLOGICAL ACTIVITY | 3M INNOVATIVE PROPERTIES CO (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017125754-A1 | ELECTRONIC BIOSENSOR | DE MONTFORT UNIVERSITY (GB) | 2017-07-27 | — | — | WO | disclosed |
| US-6420130-B1 | CHEMICAL COMPOUND FOR USE IN THE DETECTION OF PREFERENTIAL ENZYMATIC POLYPEPTIDE | AURORA BIOSCIENCES CORPORATION | 2002-07-16 | — | — | US | disclosed |
| EP-1140888-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | Aurora Biosciences Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6143492-A | COMPOUND USEFUL AS AN OPTICAL PROBE; DRUG SCREENING | AURORA BIOSCIENCES CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000035900-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | AURORA BIOSCIENCES CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
| US-5811389-A | INHIBITING PLATELET AGGREGATION; BLOOD DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5811548-A | USEFUL AS RESEARCH TOOLS IN THE DETERMINATION OF BIOLOGICALLY ACTIVE PEPTIDE SEQUENCES | HOFFMANN-LA ROCHE INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5208332-A | Optical probe for the cytochrome P-450 cholesterol side chain cleavage enzyme | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1993-05-04 | — | — | US | disclosed |
| US-5110725-A | Optical probe for the cytochrome P-450 cholesterol side chain cleavage enzyme | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246109-A1 | POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP1B1, CYP27A1 | APP 4214/4885CYP1A2 18/4885SNCA 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.